drug
Wednesday, November 6, 2024
Williamsville – Lithium aspartate is not suitable – at least in low doses – for the treatment of long-term neurological symptoms of COVID-19 such as fatigue and cognitive dysfunction. The potential effectiveness at higher doses, demonstrated by this study, still needs to be investigated, emphasize the study authors in JAMA Network Open (2024; DOI: 10.1001/jamanetworkopen.2024.36874). “Millions of people who…